

Pascual Sanchez-Juan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11564481/publications.pdf>

Version: 2024-02-01

77
papers

7,520
citations

136950

32
h-index

69250

77
g-index

85
all docs

85
docs citations

85
times ranked

11070
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	21.4	1,962
2	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924.	7.4	1,166
3	Rare coding variants in PLCC2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	21.4	783
4	Prevalence of Amyloid PET Positivity in Dementia Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1939.	7.4	501
5	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. <i>Nature Genetics</i> , 2021, 53, 294-303.	21.4	198
6	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	12.8	140
7	Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt-Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years. <i>Brain</i> , 2012, 135, 3051-3061.	7.6	135
8	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	11.0	133
9	Prevalence of amyloid- β pathology in distinct variants of primary progressive aphasia. <i>Annals of Neurology</i> , 2018, 84, 729-740.	5.3	132
10	Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. <i>Neurology</i> , 2015, 85, 626-633.	1.1	131
11	MicroRNA Profile in Patients with Alzheimer's Disease: Analysis of miR-9-5p and miR-598 in Raw and Exosome Enriched Cerebrospinal Fluid Samples. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 483-491.	2.6	126
12	Cortical microstructural changes along the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2018, 14, 340-351.	0.8	122
13	Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project. <i>Alzheimer's and Dementia</i> , 2019, 15, 1333-1347.	0.8	111
14	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	9.0	97
15	Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia. <i>Neurobiology of Aging</i> , 2014, 35, 444.e1-444.e4.	3.1	92
16	A nonsynonymous mutation in PLCC2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. <i>Acta Neuropathologica</i> , 2019, 138, 237-250.	7.7	87
17	Olfaction and imaging biomarkers in premotor <i>LRRK2</i> G2019S-associated Parkinson disease. <i>Neurology</i> , 2013, 80, 621-626.	1.1	81
18	Cerebrospinal fluid biomarkers in human genetic transmissible spongiform encephalopathies. <i>Journal of Neurology</i> , 2009, 256, 1620-1628.	3.6	77

#	ARTICLE	IF	CITATIONS
19	Relationship between cortical thickness and cerebrospinal fluid YKL-40 in prodementia stages of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 2018-2023.	3.1	75
20	Practical utility of amyloid and FDG-PET in an academic dementia center. <i>Neurology</i> , 2014, 82, 230-238.	1.1	74
21	Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis. <i>Journal of Neurology</i> , 2007, 254, 901-906.	3.6	72
22	Age-dependent association of KIBRA genetic variation and Alzheimer's disease risk. <i>Neurobiology of Aging</i> , 2009, 30, 322-324.	3.1	69
23	Spinal nerve involvement in early Guillain-Barré syndrome: A clinico-electrophysiological, ultrasonographic and pathological study. <i>Clinical Neurophysiology</i> , 2015, 126, 810-819.	1.5	62
24	Prevalence of the apolipoprotein E ϵ 4 allele in amyloid β 2 positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.8	58
25	Association of genetic variants of ABCA1 with Alzheimer's disease risk. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007, 144B, 964-968.	1.7	42
26	Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: a genome-wide association study. <i>Lancet Neurology</i> , The, 2020, 19, 840-848.	10.2	42
27	Prospective clinical and DaT-SPECT imaging in premotor <i>LRRK2</i> G2019S-associated Parkinson disease. <i>Neurology</i> , 2017, 89, 439-444.	1.1	41
28	High frequency and reduced penetrance of <i>IRRK2</i> g2019S mutation among Parkinson's disease patients in Cantabria (Spain). <i>Movement Disorders</i> , 2011, 26, 2343-2346.	3.9	40
29	Genome-wide study links <i>MTMR7</i> gene to variant Creutzfeldt-Jakob risk. <i>Neurobiology of Aging</i> , 2012, 33, 1487.e21-1487.e28.	3.1	40
30	Neurodegenerative Disease Phenotypes in Carriers of <i>MAPT</i> p.A152T, A Risk Factor for Frontotemporal Dementia Spectrum Disorders and Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2013, 27, 302-309.	1.3	40
31	Genetic variability related to serum uric acid concentration and risk of Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 1737-1740.	3.9	39
32	Interaction between <i>HMGCR</i> and <i>ABCA1</i> cholesterol-related genes modulates Alzheimer's disease risk. <i>Brain Research</i> , 2009, 1280, 166-171.	2.2	38
33	The sex-specific associations of the aromatase gene with Alzheimer's disease and its interaction with <i>IL10</i> in the Epistasis Project. <i>European Journal of Human Genetics</i> , 2014, 22, 216-220.	2.8	35
34	Binge Drinking in Young University Students Is Associated with Alterations in Executive Functions Related to Their Starting Age. <i>PLoS ONE</i> , 2016, 11, e0166834.	2.5	35
35	<i>MAPT</i> H1 Haplotype is Associated with Late-Onset Alzheimer's Disease Risk in <i>APOE</i> ϵ 4 Noncarriers: Results from the Dementia Genetics Spanish Consortium. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 343-352.	2.6	32
36	Transethnic meta-analysis of rare coding variants in <i>PLCG2</i> , <i>ABI3</i> , and <i>TREM2</i> supports their general contribution to Alzheimer's disease. <i>Translational Psychiatry</i> , 2019, 9, 55.	4.8	32

#	ARTICLE	IF	CITATIONS
37	Identification of candidate genes for Parkinson's disease through blood transcriptome analysis in LRRK2-G2019S carriers, idiopathic cases, and controls. <i>Neurobiology of Aging</i> , 2015, 36, 1105-1109.	3.1	31
38	Comparative blood transcriptome analysis in idiopathic and LRRK2 G2019S-associated Parkinson's disease. <i>Neurobiology of Aging</i> , 2016, 38, 214.e1-214.e5.	3.1	31
39	Ganglion cell layer thinning in prodromal Alzheimer's disease defined by amyloid PET. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 570-578.	3.7	31
40	Association of Rare <i>APOE</i> Missense Variants V236E and R251G With Risk of Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 652.	9.0	31
41	Source of Variant Creutzfeldt-Jakob Disease outside United Kingdom. <i>Emerging Infectious Diseases</i> , 2007, 13, 1166-1169.	4.3	29
42	A Genome Wide Association Study Links Glutamate Receptor Pathway to Sporadic Creutzfeldt-Jakob Disease Risk. <i>PLoS ONE</i> , 2015, 10, e0123654.	2.5	28
43	The MAPT H1 Haplotype Is a Risk Factor for Alzheimer's Disease in <i>APOE</i> ϵ 4 Non-carriers. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 327.	3.4	27
44	Atrophy of Basal Forebrain Initiates with Tau Pathology in Individuals at Risk for Alzheimer's Disease. <i>Cerebral Cortex</i> , 2020, 30, 2083-2098.	2.9	25
45	Serum uric acid and risk of dementia in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 637-639.	2.2	23
46	Amyloid Imaging With 11C-PIB in Patients With Cognitive Impairment in a Clinical Setting. <i>Clinical Nuclear Medicine</i> , 2016, 41, e18-e23.	1.3	22
47	Epistasis Between Intracellular Cholesterol Trafficking-Related Genes (NPC1 and ABCA1) and Alzheimer's Disease Risk. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 619-625.	2.6	21
48	Physical Activity Is Associated With Better Executive Function in University Students. <i>Frontiers in Human Neuroscience</i> , 2020, 14, 11.	2.0	21
49	A polymorphism in the regulatory region of PRNP is associated with increased risk of sporadic Creutzfeldt-Jakob disease. <i>BMC Medical Genetics</i> , 2011, 12, 73.	2.1	18
50	Very early Guillain-Barré syndrome: A clinical-electrophysiological and ultrasonographic study. <i>Clinical Neurophysiology Practice</i> , 2020, 5, 1-9.	1.4	17
51	Distinctive Oculomotor Behaviors in Alzheimer's Disease and Frontotemporal Dementia. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 603790.	3.4	17
52	Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups. <i>Brain</i> , 2022, 145, 1757-1762.	7.6	17
53	Cognitive and Behavioral Profiles of Left and Right Semantic Dementia: Differential Diagnosis with Behavioral Variant Frontotemporal Dementia and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 1129-1144.	2.6	16
54	Genetic variation in caspase-1 as predictor of accelerated progression from mild cognitive impairment to Alzheimer's disease. <i>Journal of Neurology</i> , 2011, 258, 1538-1539.	3.6	11

#	ARTICLE	IF	CITATIONS
55	The Epistasis Project: A Multi-Cohort Study of the Effects of BDNF, DBH, and SORT1 Epistasis on Alzheimer's Disease Risk. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1535-1547.	2.6	11
56	Evaluation of choroidal thickness in prodromal Alzheimer's disease defined by amyloid PET. <i>PLoS ONE</i> , 2020, 15, e0239484.	2.5	11
57	Major Surgery Affects Memory in Individuals with Cerebral Amyloid- β^2 Pathology. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 863-874.	2.6	9
58	Genetic Architecture of Primary Tauopathies. <i>Neuroscience</i> , 2023, 518, 27-37.	2.3	9
59	Caspase-1 genetic variation is not associated with Alzheimer's disease risk. <i>BMC Medical Genetics</i> , 2010, 11, 32.	2.1	8
60	Cerebral changes and disrupted gray matter cortical networks in asymptomatic older adults at risk for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 64, 58-67.	3.1	8
61	The retinal ganglion cell layer reflects neurodegenerative changes in cognitively unimpaired individuals. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 57.	6.2	8
62	Diagnostic role of ^{11}C -Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnesic and nonamnesic mild cognitive impairment patients. <i>Nuclear Medicine Communications</i> , 2016, 37, 1189-1196.	1.1	7
63	A Brief Drawing Task for the Differential Diagnosis of Semantic Dementia. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 151-160.	2.6	7
64	A unicenter, prospective study of Guillain-Barré syndrome in Spain. <i>Acta Neurologica Scandinavica</i> , 2019, 139, 546-554.	2.1	6
65	Long runs of homozygosity are associated with Alzheimer's disease. <i>Translational Psychiatry</i> , 2021, 11, 142.	4.8	6
66	Serial DaTSCPECT imaging in asymptomatic carriers of <i>LRRK2</i> G2019S mutation: 8 years' follow-up. <i>European Journal of Neurology</i> , 2021, 28, 4204-4208.	3.3	6
67	Utility of Amyloid and FDG-PET in Clinical Practice: Differences Between Secondary and Tertiary Care Memory Units. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 1025-1033.	2.6	5
68	A 5-year longitudinal evaluation in patients with mild cognitive impairment by ^{11}C -PIB PET/CT. <i>Nuclear Medicine Communications</i> , 2019, 40, 525-531.	1.1	5
69	Genetic architecture of neurodegenerative dementias. <i>Neuropharmacology</i> , 2020, 168, 108014.	4.1	5
70	LAMP2 deficiency attenuates the neurodegeneration markers induced by HSV-1 infection. <i>Neurochemistry International</i> , 2021, 146, 105032.	3.8	5
71	The unexpected co-occurrence of GRN and MAPT p.A152T in Basque families: Clinical and pathological characteristics. <i>PLoS ONE</i> , 2017, 12, e0178093.	2.5	5
72	Challenges at the APOE locus: a robust quality control approach for accurate APOE genotyping. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 22.	6.2	5

#	ARTICLE	IF	CITATIONS
73	Sensor-based gait analysis in the premotor stage of LRRK2 G2019S-associated Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2022, 98, 21-26.	2.2	5
74	Nerve ultrasonography in early Guillain-Barré syndrome: a need for large prospective studies. <i>Journal of the Peripheral Nervous System</i> , 2014, 19, 344-344.	3.1	3
75	Characterization of Alzheimer's Disease Micro-RNA Profile in Exosome-Enriched CSF Samples. <i>Methods in Molecular Biology</i> , 2019, 2044, 343-352.	0.9	3
76	Alzheimer's disease research progress in the Mediterranean region: The Alzheimer's Association International Conference Satellite Symposium. <i>Alzheimer's and Dementia</i> , 2022, 18, 1957-1968.	0.8	2
77	A snake that bites its own tail. Acquisition and loss of concepts in children and semantic dementia patients through the analysis of drawings. <i>Cortex</i> , 2020, 128, 162-173.	2.4	1